With 121 years of history, Butantan works to prevent deseases like Covid-19, flu, tetanus, diphtheria, hepatitis A and B, chikungunya, whooping cough, dengue, HPV and rabies. In 2021, Butantan produced:
Instituto Butantan is the main producer of immunobiologicals in Brazil. It is responsible for a considerable percentage of the national production of hyperimmune sera and vaccine antigens, which make up the vaccines used in the National Immunization Program (Programa Nacional de Imunizações, PNI) of the Brazilian Ministry of Health. Our technological development activities in the production of health inputs are associated with the production of vaccines, antitoxins and antivenoms, and biopharmaceuticals for human use.
Decree no. 878-A, of February 23, 1901- Law providing for the Instituto
Serumtherapico, predecessor of Instituto Butantan.
Decree no. 64,518, of October 10, 2019- Law providing for the reorganization of Instituto Butantan.